Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: DOXORUBICIN, . Treffer: 77

2021

Hatzl, S; Posch, F; Rezai, A; Gornicec, M; Beham-Schmid, C; Magnes, T; Wangner, S; Deutsch, A; Greinix, H; Uhl, B; Prochazka, KT; Egle, A; Greil, R; Melchardt, T; Linkesch, W; Schulz, E; Neumeister, P Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.
Support Care Cancer. 2021; 29(9):5197-5207 Doi: 10.1007/s00520-021-06059-2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Scheipl, S; Barnard, M; Lohberger, B; Zettl, R; Brcic, I; Liegl-Atzwanger, B; Rinner, B; Meindl, C; Fröhlich, E Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
Cell Oncol (Dordr). 2021; 44(6):1231-1242 Doi: 10.1007/s13402-021-00632-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Seeber, A; Weiss, L; Romeder, F; Szkandera, J; Kuehr, T; Kostner, S; Pichler, P; Jaeger, T; Kocher, F; Greil, R; Brodowicz, T Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
Wien Klin Wochenschr. 2021; 133(1-2):21-25 Doi: 10.1007/s00508-019-01556-1
Web of Science PubMed FullText FullText_MUG

 

2020

Harter, P; Pautier, P; Van Nieuwenhuysen, E; Reuss, A; Redondo, A; Lindemann, K; Kurzeder, C; Petru, E; Heitz, F; Sehouli, J; Degregorio, N; Wimberger, P; Burges, A; Cron, N; Ledermann, J; Lorusso, D; Paoletti, X; Marme, F Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Int J Gynecol Cancer. 2020; 30(12): 1997-2001. Doi: 10.1136/ijgc-2020-001572
Web of Science PubMed FullText FullText_MUG

 

Lohberger, B; Bernhart, E; Stuendl, N; Glaenzer, D; Leithner, A; Rinner, B; Bauer, R; Kretschmer, N Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway.
Phytomedicine. 2020; 76: 153262-153262. Doi: 10.1016/j.phymed.2020.153262 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Schliemann, C; Kerkhoff, A; Hesse, P; Bröckling, S; Hardes, J; Streitbürger, A; Andreou, D; Gosheger, G; Elges, S; Wardelmann, E; Hartmann, W; Mesters, R; Lenz, G; Willich, N; Kriz, J; Eich, H; Berdel, WE; Kessler, T Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.
PLoS One. 2018; 13(5): e0197315 Doi: 10.1371/journal.pone.0197315 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wienerroither, V; Sauerschnig, M; Beham-Schmid, C; Mathew, E; El-Shabrawi, A; Mischinger, HJ; Kornprat, P Operative R0 resection of diffuse large B-cell lymphoma of the pelvis: a case report.
J Med Case Rep. 2018; 12(1):293 Doi: 10.1186/s13256-018-1838-1 (- Case Report) [OPEN ACCESS]
PubMed FullText FullText_MUG

 

2017

Baar, MP; Brandt, RMC; Putavet, DA; Klein, JDD; Derks, KWJ; Bourgeois, BRM; Stryeck, S; Rijksen, Y; van Willigenburg, H; Feijtel, DA; van der Pluijm, I; Essers, J; van Cappellen, WA; van IJcken, WF; Houtsmuller, AB; Pothof, J; de Bruin, RWF; Madl, T; Hoeijmakers, JHJ; Campisi, J; de Keizer, PLJ Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.
Cell. 2017; 169(1):132-147 Doi: 10.1016/j.cell.2017.02.031 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Bernhart, E; Stuendl, N; Kaltenegger, H; Windpassinger, C; Donohue, N; Leithner, A; Lohberger, B Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.
Oncotarget. 2017; 8(44):77254-77267 Doi: 10.18632/oncotarget.20460 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Berry, V; Basson, L; Bogart, E; Mir, O; Blay, JY; Italiano, A; Bertucci, F; Chevreau, C; Clisant-Delaine, S; Liegl-Antzager, B; Tresch-Bruneel, E; Wallet, J; Taieb, S; Decoupigny, E; Le Cesne, A; Brodowicz, T; Penel, N REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Cancer. 2017; 123(12):2294-2302 Doi: 10.1002/cncr.30661 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ferrari, S; Bielack, SS; Smeland, S; Longhi, A; Egerer, G; Sundby Hall, K; Donati, D; Kevric, M; Brosjö, O; Comandone, A; Werner, M; Monge, O; Palmerini, E; Berdel, WE; Bjerkehagen, B; Paioli, A; Lorenzen, S; Eriksson, M; Gambarotti, M; Tunn, PU; Jebsen, NL; Cesari, M; von Kalle, T; Ferraresi, V; Schwarz, R; Bertulli, R; Kasparek, AK; Grignani, G; Krasniqi, F; Sorg, B; Hecker-Nolting, S; Picci, P; Reichardt, P EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Tumori. 2017; 104(1):30-36 Doi: 10.5301/tj.5000696
Web of Science PubMed FullText FullText_MUG

 

Longhi, A; Bielack, SS; Grimer, R; Whelan, J; Windhager, R; Leithner, A; Gronchi, A; Biau, D; Jutte, P; Krieg, AH; Klenke, FM; Grignani, G; Donati, DM; Capanna, R; Casanova, J; Gerrand, C; Bisogno, G; Hecker-Nolting, S; De Lisa, M; D'Ambrosio, L; Willegger, M; Scoccianti, G; Ferrari, S Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.
Eur J Cancer. 2017; 74(1):9-16 Doi: 10.1016/j.ejca.2016.12.016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Mir, O; Brodowicz, T; Italiano, A; Wallet, J; Blay, JY; Bertucci, F; Chevreau, C; Piperno-Neumann, S; Bompas, E; Salas, S; Perrin, C; Delcambre, C; Liegl-Atzwanger, B; Toulmonde, M; Dumont, S; Ray-Coquard, I; Clisant, S; Taieb, S; Guillemet, C; Rios, M; Collard, O; Bozec, L; Cupissol, D; Saada-Bouzid, E; Lemaignan, C; Eisterer, W; Isambert, N; Chaigneau, L; Cesne, AL; Penel, N Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2016; 17(12):1732-1742 Doi: 10.1016/S1470-2045(16)30507-1
Web of Science PubMed FullText FullText_MUG

 

Sehouli, J; Chekerov, R; Reinthaller, A; Richter, R; Gonzalez-Martin, A; Harter, P; Woopen, H; Petru, E; Hanker, LC; Keil, E; Wimberger, P; Klare, P; Kurzeder, C; Hilpert, F; Belau, AK; Zeimet, A; Bover-Barcelo, I; Canzler, U; Mahner, S; Meier, W Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Ann Oncol. 2016; 27(12):2236-2241 Doi: 10.1093/annonc/mdw418 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Sysa-Shah, P; Tocchetti, CG; Gupta, M; Rainer, PP; Shen, X; Kang, BH; Belmonte, F; Li, J; Xu, Y; Guo, X; Bedja, D; Gao, WD; Paolocci, N; Rath, R; Sawyer, DB; Naga Prasad, SV; Gabrielson, K Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Cardiovasc Res. 2016; 109(3):358-373 Doi: 10.1093/cvr/cvv274 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Brodowicz, T; Liegl-Atzwager, B; Tresch, E; Taieb, S; Kramar, A; Gruenwald, V; Vanseymortier, M; Clisant, S; Blay, JY; Le Cesne, A; Penel, N Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
BMC Cancer. 2015; 15(4):127-127 Doi: 10.1186/s12885-015-1143-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lamm, W; Wohlfarth, P; Bojic, M; Schörgenhofer, C; Drach, J; Gisslinger, H; Worel, N; Schiefer, A; Schulenburg, A; Agis, H; Kalhs, P; Greinix, HT; Schellongowski, P; Rabitsch, W Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience.
Oncology. 2015; 89(4): 196-204. Doi: 10.1159/000437055
Web of Science PubMed FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

Stotz, M; Gerger, A; Haybaeck, J; Kiesslich, T; Bullock, MD; Pichler, M Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Anticancer Res. 2015; 35(11):5737-5744
Web of Science PubMed

 

Volgger, B; Zeimet, AG; Reinthaller, A; Petru, E; Schauer, C; Klein, M; Sevelda-Schwarzgruber, U; Bogner, G; Wolfram, G; Marth, C Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Int J Gynecol Cancer. 2015; 25(2):257-262 Doi: 10.1097/IGC.0000000000000352 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wasle, I; Gamerith, G; Kocher, F; Mondello, P; Jaeger, T; Walder, A; Auberger, J; Melchardt, T; Linkesch, W; Fiegl, M; Mian, M Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.
Ann Hematol. 2015; 94(4):593-601 Doi: 10.1007/s00277-014-2250-6
Web of Science PubMed FullText FullText_MUG

 

2014

Birngruber, T; Raml, R; Gladdines, W; Gatschelhofer, C; Gander, E; Ghosh, A; Kroath, T; Gaillard, PJ; Pieber, TR; Sinner, F Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
J Pharm Sci. 2014; 103(7):1945-1948 Doi: 10.1002/jps.23994
Web of Science PubMed FullText FullText_MUG

 

Mian, M; Wasle, I; Gamerith, G; Mondello, P; Melchardt, T; Jäger, T; Linkesch, W; Fiegl, M R-CHOP versus R-COMP: are they really equally effective?
Clin Oncol (R Coll Radiol). 2014; 26(10):648-652 Doi: 10.1016/j.clon.2014.05.012
Web of Science PubMed FullText FullText_MUG

 

Welte, S; Urbanik, T; Elßner, C; Kautz, N; Koehler, BC; Waldburger, N; Bermejo, JL; Pinna, F; Weiss, KH; Schemmer, P; Jaeger, D; Longerich, T; Breuhahn, K; Schulze-Bergkamen, H Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.
PLoS One. 2014; 9(10):e110591-e110591 Doi: 10.1371/journal.pone.0110591 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Gottschalk, B; Klein, A Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.
Mol Cell Biochem. 2013; 379(1-2): 213-227. Doi: 10.1007/s11010-013-1643-5
Web of Science PubMed FullText FullText_MUG

 

Lin, S; Hoffmann, K; Xiao, Z; Jin, N; Galli, U; Mohr, E; Büchler, MW; Schemmer, P MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma.
Cancer Cell Int. 2013; 13(1):3-3 Doi: 10.1186/1475-2867-13-3 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

van Oosterwijk, JG; Meijer, D; van Ruler, MA; van den Akker, BE; Oosting, J; Krenács, T; Picci, P; Flanagan, AM; Liegl-Atzwanger, B; Leithner, A; Athanasou, N; Daugaard, S; Hogendoorn, PC; Bovée, JV Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
Am J Pathol. 2013; 182(4):1347-1356 Doi: 10.1016/j.ajpath.2012.12.036 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Lohberger, B; Rinner, B; Stuendl, N; Absenger, M; Liegl-Atzwanger, B; Walzer, SM; Windhager, R; Leithner, A Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma.
PLoS One. 2012; 7(8):e43664-e43664 Doi: 10.1371/journal.pone.0043664 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Zeimet, AG; Sevelda, P; Seifert, M; Singer, C; Hubalek, M; Angleitner-Boubenizek, L; Speiser, P; Benedicic, C; Stummvoll, W; Reinthaller, A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Wien Klin Wochenschr. 2012; 124(11-12):412-418 Doi: 10.1007/s00508-012-0185-2
Web of Science PubMed FullText FullText_MUG

 

Shirsath, NP; Manohar, SM; Joshi, KS P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Mol Cancer. 2012; 11:77-77 Doi: 10.1186/1476-4598-11-77 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Bugger, H; Guzman, C; Zechner, C; Palmeri, M; Russell, KS; Russell, RR Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation.
Cancer Chemother Pharmacol. 2011; 67(6): 1381-1388. Doi: 10.1007/s00280-010-1441-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kurtz, JE; Kaminsky, MC; Floquet, A; Veillard, AS; Kimmig, R; Dorum, A; Elit, L; Buck, M; Petru, E; Reed, N; Scambia, G; Varsellona, N; Brown, C; Pujade-Lauraine, E; on behalf of Gynecologic Cancer Intergroup Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
ANN ONCOL. 2011; 22(11): 2417-2423. Doi: 10.1093/annonc/mdr001 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2010

Burdach, S; Thiel, U; Schöniger, M; Haase, R; Wawer, A; Nathrath, M; Kabisch, H; Urban, C; Laws, HJ; Dirksen, U; Steinborn, M; Dunst, J; Jürgens, H Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases.
Bone Marrow Transplant. 2010; 45(3): 483-489. Doi: 10.1038/bmt.2009.184 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hoffmann, K; Franz, C; Xiao, Z; Mohr, E; Serba, S; Büchler, MW; Schemmer, P Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Anticancer Res. 2010; 30(11):4503-4508
Web of Science PubMed

 

Knechtel, G; Stoeger, H; Szkandera, J; Dorr, K; Beham, A; Samonigg, H Desmoid tumor treated with polychemotherapy followed by imatinib: a case report and review of the literature.
Case Rep Oncol. 2010; 3(2): 287-293. Doi: 10.1159/000318873 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

Petru, E; Reinthaller, A; Angleitner-Boubenizek, L; Schauer, C; Zeimet, A; Dirschlmayer, W; Medl, M; Stummvoll, W; Sevelda, P; Marth, C Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
WIEN KLIN WOCHENSCHR. 2010; 122(21-22): 649-652. Doi: 10.1007/s00508-010-1483-1
Web of Science PubMed FullText FullText_MUG

 

Soriţău, O; Tomuleasa, CI; Páll, E; Virág, P; Fischer-Fodor, E; Foris, V; Barbos, O; Tatomir, C; Kacsó, G; Irimie, A Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer.
Rom J Morphol Embryol. 2010; 51(2):259-264 [OPEN ACCESS]
Web of Science PubMed

 

Tomuleasa, C; Soritau, O; Rus-Ciuca, D; Pop, T; Todea, D; Mosteanu, O; Pintea, B; Foris, V; Susman, S; Kacsó, G; Irimie, A Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
J Gastrointestin Liver Dis. 2010; 19(1):61-67 [OPEN ACCESS]
Web of Science PubMed

 

2009

Deng, S; Kruger, A; Schmidt, A; Metzger, A; Yan, T; Gödtel-Armbrust, U; Hasenfuss, G; Brunner, F; Wojnowski, L Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice.
Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(1): 25-34. Doi: 10.1007/s00210-009-0407-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Feldmann, R; Schierl, M; Sittenthaler, M; Jahn, R; Wogritsch, C; Cerroni, L; Steiner, A; Breier, F Intravascular Large B-Cell Lymphoma of the Skin: Typical Clinical Manifestations and a Favourable Response to Rituximab-Containing Therapy
DERMATOLOGY. 2009; 219(4): 344-346. Doi: 10.1159/000228328
Web of Science FullText FullText_MUG Google Scholar

 

Hofmann, UB; Wobser, M; Kneitz, H; Kleine, P; Becker, JC; Brocker, EB; Ugurel, S Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp.
Br J Dermatol. 2009; 160(2):456-458 Doi: 10.1111/j.1365-2133.2008.08968.x (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Mlineritsch, B; Schabel-Moser, R; Andel, J; Fridrik, M; Moik, M; Mayer, P; Russ, G; Rass, C; Greil, R; Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Onkologie. 2009; 32(1-2):18-24 Doi: 10.1159/000180915
Web of Science PubMed FullText FullText_MUG

 

Wobser, M; Kurzinger, N; Ugurel, S; Brocker, EB; Becker, JC Therapy of metastasized Merkel cell carcinoma with liposomal doxorubicin in combination with radiotherapy.
J Dtsch Dermatol Ges. 2009; 7(6):521-525 Doi: 10.1111/j.1610-0387.2008.06990.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Kidd, M; Schally, AV; Pfragner, R; Malfertheiner, MV; Modlin, IM Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Cancer. 2008; 112(6): 1404-1414. Doi: 10.1002/cncr.23303 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leyvraz, S; Pampallona, S; Martinelli, G; Ploner, F; Perey, L; Aversa, S; Peters, S; Brunsvig, P; Montes, A; Lange, A; Yilmaz, U; Rosti, G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
J Natl Cancer Inst. 2008; 100(8): 533-541. Doi: 10.1093/jnci/djn088 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Deng, S; Kulle, B; Hosseini, M; Schlüter, G; Hasenfuss, G; Wojnowski, L; Schmidt, A Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity.
Eur J Heart Fail. 2007; 9(10): 986-994. Doi: 10.1016/j.ejheart.2007.07.016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2006

Kerl, K; Prins, C; Cerroni, L; French, LE Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
BRIT J DERMATOL. 2006; 154(5): 988-991. Doi: 10.1111/j.1365-2133.2006.07151.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Kobayashi, S; Lackey, T; Huang, Y; Bisping, E; Pu, WT; Boxer, LM; Liang, Q Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in vivo.
FASEB J. 2006; 20(6):800-802 Doi: 10.1096/fj.05-5426fje [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Angleitner-Boubenizek, L; Reinthaller, A; Deibl, M; Zeimet, AG; Volgger, B; Stempfl, A; Marth, C Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Gynecol Oncol. 2006; 102(2):226-229 Doi: 10.1016/j.ygyno.2005.12.017
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Fridrik, MA; Hausmaninger, H; Linkesch, W; Greil, R; Krieger, O; Baldinger, C; Klocker, J; Pont, J; Oberaigner, W Long-term results of dose density therapy in patients with aggressive lymphoma.
ANN HEMATOL. 2005; 84(4): 217-222. Doi: 10.1007/s00277-004-0936-x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Weitere 50 Treffer anzeigen

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum